Superworth

Ardelyx price to sales ratio ARDX

Market value divided by revenue over the last twelve months, since 2015.

Today, Oct 23, 2026
1.7×
8-year median
11.9×
Against its 8-year history
0th
percentile: 0 is its lowest day, 100 its highest
8-year range
1.7× to 113×
Peer median
1.5×

Ardelyx's price to sales ratio is 1.7× as of Oct 23, 2026.

That is below its 8-year median of 11.9×, lower than on 100% of days in the last 8 years.

Over that time it ranged from 1.7× in Oct 2026 to 113× in Apr 2021.

The median for 10 large drugmakers of a similar size is 1.5×.

Price to sales ratio over time

The dashed line is the 8-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.7×1.7×4.7×
20253.5×2.4×5.4×
20244.9×4.5×17.5×
202310.7×6.2×66.8×
202259.3×7.0×59.3×
202111.4×9.0×113×
202073.0×54.9×108×
201956.2×56.2×89.6×
2018n/m a value too high to mean anything
2017n/m a value too high to mean anything
201614.8×7.8×15.4×
201515.5×5.2×17.0×

Against its peers

Companies in Drug Manufacturers - General nearest Ardelyx's size, closest first, today.

CompanyPrice to sales ratio
ARDXArdelyx1.7×
COLLCollegium Pharmaceutical0.9×
ABUSArbutus Biopharma4.6×
CRMDCorMedix1.3×
ZVRAZevra Therapeutics4.3×
IRWDIronwood Pharmaceuticals1.5×
PBYIPuma Biotechnology2.5×
AMPHAmphastar Pharmaceuticals1.5×
OMEROmerosn/m
ARVNArvinas1.5×
PCRXPacira BioSciences1.9×
Peer median1.5×

Where Ardelyx ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Ardelyx

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.